Pay in 4 interest-free payments of $5.87 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
Beginning July 1, 2026, the Medicare GLP-1 Bridge Program may allow eligible Medicare Part D patients to access certain obesity-indicated GLP-1 medications, including Foundayo, Wegovy, and certain Zepbound formulations, for no more than $50 per month through December 31, 2027
Krauss, W.H
Kiourtis, C
It was originally approved for treating low sexual desire, also known as hypoactive sexual desire (PT-141 libido), in premenopausal women
US$ 26.95
:max_bytes(150000):strip_icc()/Health-GettyImages-2236560849-a1934f1e4c004a19835cb508d021388b.jpg)
US$ 26.72
US$ 27.59
,type=downsize)
